Skip to main content
SpringerLink
Log in

Evolving Approaches to Type 1 Diabetes Management

  • Chapter
  • First Online:
Precision Medicine in Diabetes

  • 665 Accesses

Abstract

Type 1 diabetes (T1D) is a lifelong condition with serious acute and chronic complications. Current therapies are inadequate to achieve desired metabolic control and to prevent complications. Potential new strategies for treating T1D include the development of automated insulin delivery systems, the interruption of the immune-mediated beta-cell damage and destruction, the replacement of beta cells through pancreas or islet cell transplantation, or the creation of insulin-secreting cells derived from either human embryonic stem cells or induced pluripotent stem cells. Much progress has been made in these directions. However, obstacles still remain and must be overcome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Clemens AH, Chang PH, Myers RW. The development of Biostator, a glucose controlled insulin infusion system (GCIIS). Horm Metab Res Suppl. 1977;7:23–33.

    CAS  Google Scholar 

  2. Pickup JC, Keen H, Parsons JA, Alberti KGMM. Continuous subcutaneous insulin infusion: an approach to achieving normoglycemia. Br Med J. 1978;1:204–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med. 1979;300:573–8.

    Article  CAS  PubMed  Google Scholar 

  4. Skyler JS, Seigler DE, Reeves ML. Optimizing pumped insulin delivery. Diabetes Care. 1982;5:135–9.

    Article  CAS  PubMed  Google Scholar 

  5. Farkas-Hirsch R, Hirsch I. Continuous subcutaneous insulin infusion: a review of the past and its implementation for the future. Diabetes Spectrum. 1994;7(80-84):136–8.

    Google Scholar 

  6. Renard E. Implantable closed-loop glucose-sensing and insulin delivery: the future for insulin pump therapy. Curr Opin Pharmacol. 2002;2:708–16.

    Article  CAS  PubMed  Google Scholar 

  7. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol. 2011;7:385–95.

    Article  CAS  PubMed  Google Scholar 

  8. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31:934–9.

    Article  PubMed  Google Scholar 

  9. Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381:1707–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, et al. A randomized trial of closed-loop control inchildren with type 1 diabetes. N Engl J Med. 2020;383:836–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Brown SA, Forlenza GP, Bode BW, Pinsker JE, Levy CJ, Criego AB, at al. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care. 2021;44:1630–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Collyns OJ, Meier RA, Betts ZL, Chan DSH, Frampton C, Frewen CM, et al. Improved glycemic outcomes with medtronic minimed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care. 2021;44:969–75.

    Article  CAS  PubMed  Google Scholar 

  13. Fuchs J, Allen JM, Boughton CK, Wilinska ME, Thankamony A, de Beaufort C, et al. Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAP02 study): an open-label, multicentre, multinational, randomised cross-over study protocol. BMJ Open. 2021;11(2):e042790.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kovatchev B. A century of diabetes technology: signals, models, and artificial pancreas control. Trends Endocrinol Metab. 2019;30:432–44.

    Article  CAS  PubMed  Google Scholar 

  15. El-Khatib FH, Russell SJ, Magyar KL, Sinha M, McKeon K, Nathan DM, et al. Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes. J Clin Endocrinol Metab. 2014;99:1701–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Russell SJ, El-Khatib FH, Sinha M, Magyar KL, McKeon K, Goergen LG, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371:313–25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. El-Khatib FH, Balliro C, Hillard MA, Magyar KL, Ekhlaspour L, Sinha M, et al. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017;389:369–80.

    Article  CAS  PubMed  Google Scholar 

  18. Haidar A, Tsoukas MA, Bernier-Twardy S, Yale JF, Rutkowski J, et al. A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial. Diabetes Care. 2020;43:597–606.

    Article  CAS  PubMed  Google Scholar 

  19. Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369:224–32.

    Article  CAS  PubMed  Google Scholar 

  20. Battelino T, Nimri R, Dovc K, Phillip M, Bratina N. Prevention of hypoglycemia with predictive low glucose insulin suspension in children with type 1 diabetes: a randomized controlled trial. Diabetes Care. 2017;40:764–70.

    Article  CAS  PubMed  Google Scholar 

  21. Bergenstal R, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316:1407–8.

    Article  PubMed  Google Scholar 

  22. Boughton CK, Hartnell S, Thabit H, Poettler T, Herzig D, Wilinska ME, et al. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: a double-blind, multicentre, multinational, randomized, crossover study. Diabetes Obes Metab. 2021;23:1389–96.

    Article  CAS  PubMed  Google Scholar 

  23. Garcia-Tirado J, Diaz JL, Esquivel-Zuniga R, Koravi CLK, Corbett JP, Dawson M, et al. Advanced closed-loop control system improves postprandial glycemic control compared with a hybrid closed-loop system following unannounced meal. Diabetes Care. 2021:dc210932. https://doi.org/10.2337/dc21-0932. Online ahead of print.

  24. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383:69–82.

    Article  PubMed  Google Scholar 

  25. Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M. The challenge of modulating β-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2019;7:52–64.

    Article  CAS  PubMed  Google Scholar 

  26. Roep BO, Wheeler DCS, Peakman M. Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine. Lancet Diabetes Endocrinol. 2019;7:65–74.

    Article  PubMed  Google Scholar 

  27. Jacobsen LM, Schatz DA. Insulin immunotherapy for pretype 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2021;28:390–6.

    CAS  PubMed  Google Scholar 

  28. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381:603–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13(583):eabc8980.

    Google Scholar 

  30. Feutren G, Assan R, Karsenty G, Du Rostu H, Sirmai J, Papoz L, et al. Cyclosporin increases the rate and length of remissions in insulin dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet. 1986;2:119–24.

    Article  CAS  PubMed  Google Scholar 

  31. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes. 1988;37:1574–82.

    Article  Google Scholar 

  32. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med. 1988;319:599–604.

    Article  CAS  PubMed  Google Scholar 

  33. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692–8.

    Article  CAS  PubMed  Google Scholar 

  34. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352:2598–608.

    Article  CAS  PubMed  Google Scholar 

  35. Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62:3766–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, et al. Rituximab, B-lymphocyte depletion and preservation of beta-cell function. N Engl J Med. 2009;361:2143–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised double-blind. Placebo-Controlled Trial Lancet. 2011;378:412–9.

    CAS  PubMed  Google Scholar 

  38. Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013;1:284–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, et al. Low-dose anti-thymocyte globulin preserves C-peptide and reduces A1c in new onset type 1 diabetes: two year clinical trial data. Diabetes. 2019;68:1267–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, et al. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021;9:212–24.

    Article  Google Scholar 

  41. Quattrin T, Haller MJ, Steck AK, Felner EI, Li Y, Xia Y, et al. Golimumab and beta-cell function in youth with new-onset type 1 diabetes. N Engl J Med. 2020;383:2007–17.

    Article  CAS  PubMed  Google Scholar 

  42. Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, et al. Imatinib therapy for patients with recent-onset type 1 diabetes: a randomised, double blind, multicentre, placebo controlled phase 2 trial. Lancet Diabetes Endocrinol. 2021;9:502–14.

    Article  CAS  PubMed  Google Scholar 

  43. Ziegler AG, Danne T, Dunger DB, Berner R, Puff R, Kiess W, et al. Primary prevention of beta-cell autoimmunity and type 1 diabetes - The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives. Mol Metab. 2016;5:255–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Smilek DE, Ehlers ME, Nepom GT. Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech. 2014;7:503–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Skyler JS. The prevention & reversal of type 1 diabetes – past challenges & future opportunities. Diabetes Care. 2015;38:997–1007.

    Article  PubMed  Google Scholar 

  46. Gruessner AC, Gruessner RW. Long-term outcome after pancreas transplantation: a registry analysis. Curr Opin Organ Transplant. 2016;21:377–85.

    Google Scholar 

  47. Hering BJ, Clarke WR, Bridges ND, Eggerman TL, Alejandro R, Bellin MD, et al. Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia. Diabetes Care. 2016;39:1230–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Vantyghem MC, Chetboun M, Gmyr V, Jannin A, Espiard S, Le Mapihan K, et al. Ten-year outcome of islet alone or islet after kidney transplantation in type 1 diabetes: a prospective parallel-arm cohort study. Diabetes Care. 2019;42:2042–9.

    Article  PubMed  Google Scholar 

  49. Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53:955–62.

    Article  CAS  PubMed  Google Scholar 

  50. Ricordi C, Lacy PE, Finke EH, Olack BJ, Sharp DW. Automated method for isolation of human pancreatic islets. Diabetes. 1988;37:413–20.

    Article  CAS  PubMed  Google Scholar 

  51. Baidal DA, Ricordi C, Berman DM, Alvarez A, Padilla N, Ciancio G, et al. Bioengineering of an intraabdominal endocrine pancreas. N Engl J Med. 2017;376:1887–9.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Kandaswamy R, Stock PG, Miller J, Skeans MA, White J, Wainright J, et al. OPTN/SRTR 2019 annual data report: pancreas. Am J Transplant. 2021;21(Suppl 2):138–207.

    Article  PubMed  Google Scholar 

  53. Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 2010;59:947–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Burke GW 3rd, Vendrame F, Pileggi A, Ciancio G, Reijonen H, Pugliese A. Recurrence of autoimmunity following pancreas transplantation. Curr Diab Rep. 2011;11:413–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Ludwig B, Ludwig S, Steffen A, Knauf Y, Zimerman B, Heinke S, et al. Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes. Proc Natl Acad Sci U S A. 2017;114:11745–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Niu D, Wei HJ, Lin L, George H, Wang T, Lee IH, et al. Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9. Science. 2017;357:1303–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. D'Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006;24:1392–401.

    Article  CAS  PubMed  Google Scholar 

  58. Schulz TC, Young HY, Agulnick AD, Babin MJ, Baetge EE, Bang AG, et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS One. 2012;7(5):e37004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Pagliuca FW, Millam JR, Gürtler M, Segel M, Van Devort A, Ryu JH, et al. Generation of functional human pancreatic beta cells in vitro. Cell. 2014;159:428–39.

    Google Scholar 

  60. Sneddon JB, Qizhi T, Stock P, Bluestone JA, Roy D, Desai T, et al. Stem cell therapies for treating diabetes: progress and remaining challenges. Cell Stem Cell. 2018;6:810–23.

    Article  CAS  Google Scholar 

  61. Meivar-Levy I, Ferber S. Liver to pancreas transdifferentiation. Curr Diab Rep. 2019;19:76.

    Article  PubMed  Google Scholar 

  62. Pepper AR, Bruni A, Pawlick R, O’Gorman D, Kin T, Thiesen A, et al. Posttransplant characterization of long term functional hESC-derived pancreatic endoderm grafts. Diabetes. 2019;68:953–62.

    Article  CAS  PubMed  Google Scholar 

  63. ClinicalTrials.Gov NCT04786262. A safety, tolerability, & efficacy study of VX-880 in participants with type 1 diabetes. Accessed 1 Sept, 2021.

    Google Scholar 

  64. Desai TA, Tang Q. Islet encapsulation therapy - racing towards the finish line? Nat Rev Endocrinol. 2018;14:630–2.

    Article  PubMed  Google Scholar 

  65. Stock AA, Manzoli V, De Toni T, Abreu MM, Poh YC, Ye L, et al. Conformal coating of stem cell-derived islets for beta cell replacement in type 1 diabetes. Stem Cell Reports. 2020;14:91–104.

    Article  CAS  PubMed  Google Scholar 

  66. Parent AV, Faleo G, Chavez J, Saxton M, Berrios DI, Kerper NR, et al. Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. Cell Rep. 2021;36:109538.

    Article  CAS  PubMed  Google Scholar 

  67. Zhou Q, Melton DA. Pancreas Regeneration. Nature. 2018;557:351–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Wang P, Karakose E, Choleva L, Kumar K, DeVita RJ, Garcia-Ocaña A, et al. Human beta cell regenerative drug therapy for diabetes: past achievements and future challenges. Front Endocrinol. 2021;12:671946.

    Article  Google Scholar 

  69. Skyler JS. Hope versus hype: where are we in type 1 diabetes? Diabetologia. 2018;61:509–16.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA

    Jay S. Skyler

Authors
  1. Jay S. Skyler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jay S. Skyler .

Editor information

Editors and Affiliations

  1. Division of Endocrinology, University of Virginia, Charlottesville, VA, USA

    Rita Basu

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Skyler, J.S. (2022). Evolving Approaches to Type 1 Diabetes Management. In: Basu, R. (eds) Precision Medicine in Diabetes. Springer, Cham. https://doi.org/10.1007/978-3-030-98927-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-98927-9_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-98926-2

  • Online ISBN: 978-3-030-98927-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation